Research programme: molecularly-cloaked antiretrovirals - Sequoia

Drug Profile

Research programme: molecularly-cloaked antiretrovirals - Sequoia

Alternative Names: Molecularly-cloaked antiretrovirals research programme - Sequoia; SPI 70014; SPI-30014; SPI-30014C; SPI-70038; SPI-70038C

Latest Information Update: 11 May 2011

Price : $50

At a glance

  • Originator Sequoia Pharmaceuticals
  • Class Peptides; Recombinant fusion proteins
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 19 Nov 2004 Preclinical trials in HIV infections treatment in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top